Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Last updated: January 14, 2019
Sponsor: Yuhan Corporation
Overall Status: Completed

Phase

3

Condition

Stress

Elevated Triglycerides (Hypertriglyceridemia)

Dyslipidemia

Treatment

N/A

Clinical Study ID

NCT03067688
YHP1604-301
  • Ages > 19
  • All Genders

Study Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Signed informed consent

  2. Subjects with hypertension and hyperlipidemia

Exclusion

Exclusion Criteria:

  1. Patients with known or suspected secondary hypertension

  2. Other exclusions applied

Study Design

Total Participants: 202
Study Start date:
April 11, 2017
Estimated Completion Date:
March 27, 2018

Study Description

This trial is a phase 3 study to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

In "Temisartan/Amlodipine/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine/Rosuvastatin" 8 for weeks.

In "Temisartan/Amlodipine" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine" for 8 weeks.

In "Temisartan/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Rosuvastatin" for 8 weeks.

Connect with a study center

  • Seoul Natuional University Hospital

    Seoul, Jongno 03080
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.